Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is poised for substantial revenue growth, with an anticipated annual increase of over 20% through 2026, driven by commercial sales of products like Vabysmo and recent launches such as Ojemda and Miplyffa. The Company's total income from royalty agreements surged to $28.5 million in 2024, a significant rise from $4.8 million in 2023, underscoring the effectiveness of XOMA's strategy in acquiring future economic rights and expanding its royalty aggregate. Projections for 2026 suggest revenues may reach $49.0 million, representing a 36% increase from 2025, further enhanced by potential contributions from earlier-stage assets and milestone payments, indicating a robust growth trajectory for XOMA.

Bears say

XOMA Royalty Corp has experienced revenue and net earnings variability, which stems from the fluctuations in the international market for its products; this susceptibility to global economic downturns, new tariffs, and changes in governmental reimbursement policies poses a risk to its operations. The company's reliance on the outcomes of clinical trials and its ability to secure funding for drug development further heighten the uncertainty, especially following the recent removal of a near-term revenue driver from its financial projections. Additionally, the potential departure of key executives could severely impact XOMA's operational knowledge and industry expertise, contributing to a bleak outlook for the company's stock performance.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Feb 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.